CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression
CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression
WCLC 2025: Latest in EGFR positive NSCLC
Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours
Treatment management of favourable risk and very favourable risk patients
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer
Key insights from head and neck research at ASCO 2025
ASCO 2025: Developments in the treatment of soft tissue sarcoma
Transforming cancer care in India: The Access Cancer Care Initiative
Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance
Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC